Key Developments: AngioDynamics Inc (ANGO.O)
10.71USD
24 May 2013
$0.04 (+0.37%)
$10.67
$10.64
$10.75
$10.54
66,241
121,750
$12.91
$9.52
Latest Key Developments (Source: Significant Developments)
Angiodynamics Inc Lowers FY 2013 Guidance
Angiodynamics Inc announced that for fiscal 2013, it expects sales to be between $337 million - $341 million, EBITDA to be between $50 million - $52 million and EPS to be between $0.32 - $0.35. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $341 million, EBITDA of $52 million and EPS of $0.33 for fiscal 2013. Full Article
Angiodynamics Inc Issues Q3 2013 Guidance Below Analysts' Estimates
Angiodynamics Inc announced that it expects to report net sales for the third quarter of 2013 to be approximately $82 million and expects to report adjusted net income for the third quarter in the range of $0.04 per share to $0.06 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues $89 million and EPS of $0.09 for the third quarter of 2013. Full Article
Angiodynamics Inc Completes Acquisition Of Assets Of Microsulis Medical Ltd
Angiodynamics Inc announced that it has completed the previously announced acquisition of certain assets of Microsulis Medical Ltd. Terms of the transaction were not disclosed. Full Article
Angiodynamics Inc To Acquire Certain Assets Of Microsulis Medical Ltd
Angiodynamics Inc announced that it has exercised the option to purchase certain assets of Microsulis Medical Ltd. The transaction brings to the Company a microwave ablation technology and its worldwide distribution rights. Full Article
Angiodynamics Inc Sees FY 2013 Revenue Guidance To A Slightly Lower Midpoint Of Prior Range; Reaffirms FY 2013 EPS Guidance-Conference Call
Angiodynamics Inc announced that for fiscal 2013, it guide to a slightly lower midpoint, from 5% down to 4%, on revenue at $358 million. The Company did not change earnings per share (EPS) and are still guiding to $0.40 to $0.42. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $356 million, and EPS of $0.40 for fiscal 2013. Full Article
Angiodynamics Inc Reaffirms FY 2013 Guidance; Lowers FY 2013 Revenue And EBITDA Guidance
Angiodynamics Inc announced that for fiscal 2013, it expects adjusted non-GAAP to be in the range of $355-$360 million, non-GAAP operating income to be in a range of $29-$31 million, non-GAAP EBITDA to be in a range of $56-$57 million and non-GAAP earnings per share (EPS) to be in a range $0.40-$0.42. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $360 million, EBIT of $30 million, EBITDA of $57 million and EPS of $0.40 for fiscal 2013. Full Article
Angiodynamics Inc Announces Management Changes
Angiodynamics Inc announced that Executive Vice President and Chief Financial Officer Joseph Gersuk will retire from the Company on January 31, 2013. He will be succeeded by Mark T. Frost, who was recently Chief Financial Officer and Senior Vice President of Administration of Albany Molecular Research Inc. Full Article
Levi & Korsinsky, LLP Announces Investigation Of Angiodynamics Inc
Levi & Korsinsky, LLP announced that it is investigating AngioDynamics, and its Board of Directors in connection with excessive compensation provided to certain of its executive officers. Full Article
Angiodynamics Inc Completes Acquisition Of Vortex Medical
Angiodynamics Inc announced that it has completed the acquisition of Vortex Medical Inc., a privately-held company focused on the development of medical devices for venous drainage and the removal of thrombus, or blood clots, from occluded blood vessels. Terms of the transaction were not disclosed . Full Article
Angiodynamics Inc Raises FY 2013 Revenue Guidance; Lowers FY 2013 Earnings Guidance
AngioDynamics Inc announced that for fiscal 2013, the acquisition is expected to add approximately $1 million in sales, reduce operating income by approximately $5 million, have negligible impact on EBITDA, and reduce EPS by approximately $0.09 on a GAAP and Non-GAAP basis. The Company now expects GAAP sales to be in a range $361-$364 million, adjusted non-GAAP to be in the range of $361-$364 million, GAAP operating income to be in a range of $13-$15 million, non-GAAP operating income to be in a range of $29-$31 million, GAAP EBITDA to be in a range of $44-$45 million, non-GAAP EBITDA to be in a range of $60-$61 million, GAAP earnings per share (EPS) to be in a range 0.12-0.14 and non-GAAP earnings per share (EPS) to be in a range 0.40-0.42. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
